Nektar and Collaborators Announce Preclinical Publication of Data for NKTR-255 and its Observed Improvement of NK Cell Function in Multiple MyelomaPRNewsWire • 08/16/22
Nektar to Announce Financial Results for the Second Quarter 2022 on Thursday, August 4, 2022, After Close of U.S.-Based Financial MarketsPRNewsWire • 07/26/22
Nektar Announces Promotion of Jillian B. Thomsen to Senior Vice President & Chief Financial OfficerPRNewsWire • 07/01/22
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseZacks Investment Research • 04/28/22
I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical OfficerPRNewsWire • 04/28/22
Nektar Therapeutics Announces Strategic Reorganization Plan and Corporate OutlookPRNewsWire • 04/25/22
Nektar and Collaborators Present Preclinical Data on NKTR-255, a Novel IL-15 Receptor Agonist, in combination with CAR Cell Therapies at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®PRNewsWire • 04/23/22
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors to Outline New Strategic PlanPRNewsWire • 04/22/22
Nektar, Bristol Myers Squibb end clinical development of combination therapy including OpdivoMarket Watch • 04/18/22
Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab)PRNewsWire • 04/14/22